Attovia Closes $90 Million Series C Financing for ATTOBODY Programs

Image Credit: © Pormezz - stock.adobe.com

Today, Attovia Therapeutics announced the close of a $90 million Series C financing, which will advance the company’s ATTO-1310 and ATTO-3712 through clinical proof-of-concept.¹ These assets will be used to treat chronic pruritus and atopic dermatitis, with hopes of achieving best-in-disease efficacy. The funds will also be used to expand Attovia’s pipeline and support its proprietary ATTOBODY technology, as the company continues to investigate treatments for immune-mediated conditions. The proprietary biologics technology is designed to enhance potency and allow unparalleled engineering flexibility.

The Series C round was led by Deep Track Capital and included new investors such as Vida Ventures, Sanofi Ventures, and Mirae Asset Capital Life Science, and existing partners including Frazier Life Sciences, venBio, Goldman Sachs Alternatives, Nextech Ventures, Cormorant Asset Management, EcoR1 Capital, Marshall Wace, and Illumina Ventures.

“Completing what was an oversubscribed round of financing during this time speaks to the standout potential of our platform, programs, and excellent team,” Tao Fu, Attovia’s founder and CEO, said in a news release. “We deeply appreciate the support of our exceptional investor base and the shared commitment to transforming the lives of patients living with immune-mediated diseases. We now have a multi-year runway to advance our programs expeditiously, expand our pipeline judiciously, and pursue potential partnerships, all of which should give us greater optionality for the future.”¹

The first ATTOBODY-based product candidate is ATTO-1310, a first-in-class, half-life extended anti-IL31 biologic for chronic pruritus of unknown origin (CPUO) and other similar conditions with unmet need. Currently in double-blind, placebo-controlled, phase 1 trials (NCT06787586), the drug aims to be fast-acting, convenient, and effective for CPUO, which currently has no approved treatments. The first patient was dosed in January.²

"ATTO-1310 has the potential to provide life-changing relief to patients suffering from these diseases," Hubert Chen, MD, chief medical officer at Attovia, said in a statement. "We are working with a group of international KOLs who have spent years advocating for the development of effective treatments for these patients, and who will help us drive progress in our clinical program. Advancement of ATTO-1310 into the clinic marks an important milestone for Attovia as we become a clinical-stage company delivering innovative therapies for patients with immune-mediated diseases."²

ATTO-3712, a first-in-class, dual-action anti-IL13 x IL31, half-life extended bispecific, is being developed for convenient management of atopic dermatitis and potentially chronic spontaneous urticaria, prurigo nodularis, and other inflammatory diseases. Phase 1 studies will begin later this year. The company’s pipeline also includes ATTO-004, a multi-specific therapy for inflammatory bowel disease, and 2 early-stage Development Programs for their potential in multi-disease applications.

“Attovia has created a transformative pipeline leveraging its revolutionary ATTOBODY platform,” said Rebecca Luse, Managing Director at Deep Track Capital and new member of Attovia’s Board of Directors. “We are highly impressed with the team's speed and quality of disciplined execution, and we are looking forward to supporting their growth and success as they work to realize the full potential of their platform and pipeline programs.”¹

References

1. Attovia Therapeutics Announces $90 Million Series C Financing to Advance ATTOBODY-based Programs through Clinical Proof of Concept. News release. Globe Newswire. April 15, 2025. Accessed April 15, 2025. https://www.globenewswire.com/news-release/2025/04/15/3061599/0/en/Attovia-Therapeutics-Announces-90-Million-Series-C-Financing-to-Advance-ATTOBODY-based-Programs-through-Clinical-Proof-of-Concept.html

2. Attovia Therapeutics announces first participant dosed in first-in-human phase 1 study of ATTO-1310, its novel half-life extended anti-IL-31 ATTOBODY for the treatment of chronic pruritus. News release. BioSpace. January 23, 2025. Accessed April 15, 2025. https://www.biospace.com/press-releases/attovia-therapeutics-announces-first-participant-dosed-in-first-in-human-phase-1-study-of-atto-1310-its-novel-half-life-extended-anti-il-31-attobody-for-the-treatment-of-chronic-pruritus